Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
Diabetes, Obesity and Metabolism · 2023-09 · 25 (9) · 2626-2633
DOI: 10.1111/dom.15148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 21.06.2023. Verfasst von Carel W le Roux und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Aim
To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. Materials and Methods Using SURMOUNT‐1 and STEP 1 trial data, mean percentage change in body weight from baseline and odds ratio (OR) of achieving 5% or greater weight loss were compared between tirzepatide 10 and 15 mg at week 72 and semaglutide 2.4 mg at week 68 using matching‐adjusted indirect comparison of the efficacy estimand. Sensitivity analyses were completed using different methods, including the Bucher method, also using different estimands and/or time points.
Results
Greater reductions in percentage change in body weight were observed with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg (tirzepatide 10 mg mean difference: −4.67% [95% CI −5.91%, −3.43%]; tirzepatide 15 mg mean difference: −5.92% [95% CI −7.16%, −4.68%]; both P < .001). Similarly, more participants achieved 5% or greater weight loss with tirzepatide 10 mg (OR 2.61 [95% CI 1.48, 4.57]; P < .001) and 15 mg (OR 2.75 [95% CI 1.57, 4.81]; P < .001) compared with semaglutide 2.4 mg. All sensitivity analyses were consistent, except for an OR of achieving 5% or greater weight loss with tirzepatide 10 mg using the Bucher method to analyse the treatment regimen estimand ( P = .074).
Conclusions
Currently there are no direct comparisons of tirzepatide and semaglutide for weight management. Using the matching‐adjusted indirect treatment comparison method to compare the efficacy of tirzepatide and semaglutide for chronic weight management, this analysis showed greater weight loss with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- McMaster University, York University and Wharton Weight Management Clinic, Toronto, Ontario, Canada.
ORCID-Profile: Carel W le Roux, Raleigh Malik, Ana Hickey, Luis-Emilio Garcia-Perez, Sean Wharton
Förderung
- Eli Lilly and Company
Zitieren
APA
le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia-Perez, L. E., & Wharton, S. (2023). Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison. Diabetes, Obesity and Metabolism, 25(9), 2626-2633. https://doi.org/10.1111/dom.15148
Vancouver
le Roux CW, Hankosky ER, Wang D, Malik R, Yu M, Hickey A, et al. Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison. Diabetes, Obesity and Metabolism. 2023;25(9):2626-2633. doi:10.1111/dom.15148
BibTeX
@article{leRoux2023,
author = {le Roux, Carel W and Hankosky, Emily R and Wang, Duzhe and Malik, Raleigh and Yu, Maria and Hickey, Ana and Kan, Hong and Bunck, Mathijs C and Stefanski, Adam and Garcia-Perez, Luis-Emilio and Wharton, Sean},
title = {Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
volume = {25},
number = {9},
pages = {2626--2633},
doi = {10.1111/dom.15148}
}
EUVIMED